OJMM  Vol.3 No.4 , December 2013
Detection of Extended Spectrum β-Lactamase Producing Klebsiella pneumoniae and Escherichia coli in Two Hospitals in the Federal Capital Territory, Abuja, Nigeria
ABSTRACT
In this study, the prevalence of Extended Spectrum Beta-lactamase (ESBL) producing Klebsiella pneumoniae and Escherichia coli isolates from the University of Abuja Teaching Hospital and the National Hospital was determined. A total of two hundred and fifteen (215) clinical isolates were examined, of which 60% were E. coli and 40% K. pneumoniae respectively. The isolates were collected from various samples namely: Stool, Urine, Pus, High Vagina Swab, Sputum and Wound swab. Out of these isolates, 54 of K. pneumoniae were screened to be ESBL negative and 32 as ESBL positive isolates, while 88 and 40 E. coli were also screened as ESBL negative and ESBL positive isolates respectively. These represent 37.9% of all K. pneumoniae isolates and 31.25% of E. coli isolates respectively. The prevalence of ESBL among the species was not however statistically different (p > 0.05). Multiple resistance in these isolates was common and there is the need for routine screening of ESBL in our hospitals to guide rational and effective use of antibiotics.

Cite this paper
B. Akanbi, B. Ojonuba and R. Njoku, "Detection of Extended Spectrum β-Lactamase Producing Klebsiella pneumoniae and Escherichia coli in Two Hospitals in the Federal Capital Territory, Abuja, Nigeria," Open Journal of Medical Microbiology, Vol. 3 No. 4, 2013, pp. 207-212. doi: 10.4236/ojmm.2013.34031.
References
[1]   E. A. Ashley, Y.Lubell, N. J. White and P. Turner, “Antimicrobial Susceptibility of Bacterial Isolates from Community Acquired Infections in Sub-Saharan Africa and Asian Low and Middle Income Countries,” Tropical Medicine and International Health, Vol. 16, No. 9, 2011, pp. 1167-1179. http://dx.doi.org/10.1111/j.1365-3156.2011.02822.x

[2]   D. Faith, M. Villanueva, E. Thelma, D. Tupasi, G. Homer, M. D.Abiad, Q. Benilda, M. Baello, C. Rowena and D. Cardano, “Extended Spectrum β-Lactamase Production among Escherichia coli and Klebsiella spp.,” Philippines Journal Microbiological Infectious Diseases, Vol. 32, No. 3, 2003, pp. 103-108.

[3]   R. Canton, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero and T. M. Coque, “Prevalence and Spread of Extended-Spectrum Betalactamase-Producing Enterobacteriaceae in Europe,” Clinical Microbiology and Infection, Vol. 14, Suppl. 1, 2008, pp. 144-153. http://dx.doi.org/10.1111/j.1469-0691.2007.01850.x

[4]   S. Kotapati, J. L. Kuti and C. H. Nightingale, “Clinical Implications of Extended Spectrum b-Lactamase (ESBL) Producing Klebsiella Species and Escherichia coli on Cefepime Effectiveness,” Journal of Infection, Vol. 51, No. 3, 2005, pp. 211-217.

[5]   H. Y. Sun, S. Y. Chen, S. C. Chang, S. C. Pan, C. P. Su, and Y. C. Chen, “Community-Onset Escherichia coli and Klebsiella pneumoniae bacteremia: Influence of Health Care Exposure on Antimicrobial Susceptibility,” Diagnostic Microbiology and Infectious Disease, Vol. 55, No. 2, 2006, pp. 135-141. http://dx.doi.org/10.1016/j.diagmicrobio.2006.01.004

[6]   D. L. Paterson and R. A. Bonomo, “Extended-Spectrum β-Lactamases: A Clinical Update,” Clinical Microbiology Reviews, Vol. 18, No. 4, 2005, pp. 657-686. http://dx.doi.org/10.1128/CMR.18.4.657-686.2005

[7]   M. Gniadkowski, “Evolution and Epidemiology of Extended Spectrum β-Lactamases (ESBLs) and ESBL-Producing Microorganisms,” Clinical Microbiology and Infection, Vol. 7, No. 11, 2001, pp. 597-608. http://dx.doi.org/10.1046/j.1198-743x.2001.00330.x

[8]   S. Nathisuwan, D. S. Burgess and J. S. Lewis, “Extended-Spectrum Beta-Lactamases: Epidemiology, Detection, and Treatment,” Pharmacotherapy, Vol. 21, No. 8, 2001, pp. 920-928. http://dx.doi.org/10.1592/phco.21.11.920.34529

[9]   M. F. Lin, M. L. Huang and S.H. Lai, “Risk Factors in the Acquisition of Extended-Spectrum Beta-Lactamase Klebsiella pneumoniae: A Case-Control Study in a District Teaching Hospital in Taiwan,” The Journal of Hospital Infection, Vol. 53, No. 1, 2003, pp. 39-45. http://dx.doi.org/10.1053/jhin.2002.1331

[10]   J. Tham, I. Odenholt, M. Walder, A. Brolund, J. Ahl and E. Melander, “Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Patients with Travellers’ Diarrhoea,” Scandavanian Journal of Infectious Diseases, Vol. 42, No. 4, 2010, pp. 275-280. http://dx.doi.org/10.3109/00365540903493715

[11]   F. Ndugulile, R. Jureen, S. H. W. Urassa and N. Langeland, “Extended Spectrum β-Lactamases among Gram-Negative Bacteria of Nosocomial Origin from an Intensive Care Unit of a Tertiary Health Facility in Tanzania,” BMC Infectious Diseases, Vol. 5, 2005, p. 86. http://dx.doi.org/10.1186/1471-2334-5-86

[12]   K. Bush, “Extended-Spectrum Beta-Lactamases in North America, 1987-2006,”Clinical Microbiology and Infection, Vol. 14, Suppl. 1, 2008, pp. 134-143. http://dx.doi.org/10.1111/j.1469-0691.2007.01848.x

[13]   O. O. Soge, A. M. Queenan, K. K. Ojo, B. A. Adeniyi and M. C. Roberts, “CTX-M-15 Extended-Spectrum (beta)-Lactamase from Nigerian Klebsiella pneumoniae,” The Journal of Antimicrobial Chemotherapy, Vol. 57, No.1, 2006, pp. 24-30. http://dx.doi.org/10.1093/jac/dki429

[14]   R. A. Afunwa, D. C. Odimegwu, R. I. Iroha and C. O. Esimone, “Antimicrobial Resistance Status and Prevalence Rates of Extended Spectrum Beta-Lactamase Producers Isolated from a Mixed Human Population,” Bosnian Journal of Basic Medical Sciences, Vol. 11, No. 2, 2011, pp. 91-96.

[15]   Clinical and Laboratory Standards Institute (CLSI), “Performance Standards for Antimicrobial Susceptibility Testing,” 17th Information Supplement, 17th Edition, Approved Standard M100-S17, Clinical and Laboratory Standards Institute, Wayne, 2007.

[16]   The European Committee on Antimicrobial Susceptibility Testing—EUCAST. http://www.eucast.org

[17]   E. Lautenbach, J. B. Patel, W. B. Bilker P. H. Edelstein and N. O. Fishman, “Extended-Spectrum β-Lactamase- Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Infection and Impact of Resistance on Outcomes,” Clinical Infectious Diseases, Vol. 32, No. 8 2001, pp. 1162-1171. http://dx.doi.org/10.1086/319757

[18]   R. Tsay, L. K. Siu, C. Fung and F. Chang, “Characteristics of Bacteremia Between Community-Acquired and Nosocomial Klebsiella pneumoniae Infection Risk Factor for Mortality and the Impact of Capsular Serotypes as a Herald for Community-Acquired Infection,” Archives of Internal Medicine, Vol. 162, No. 9, 2002, pp. 1021-1027. http://dx.doi.org/10.1001/archinte.162.9.1021

[19]   C. Struve and K. A. Krogfelt, “Pathogenic Potential of Environmental Klebsiella pneumoniae Isolates,” Environmental Microbiology, Vol. 6, No. 6, 2004, pp. 584-590. http://dx.doi.org/10.1111/j.1462-2920.2004.00590.x

[20]   K. Serefhanoglu, H. Turan, F. E. Timurkaynak and H. Arslan, “Bloodstream Infections Caused by ESBL-Producing E. coli and K. pneumoniae: Risk Factors for Multidrug-Resistance,” Brazilian Journal of Infectious Diseases, Vol. 13, No. 6, 2009 pp. 403-407. http://dx.doi.org/10.1590/S1413-86702009000600003

[21]   D. L. Paterson, “Resistance in Gram-Negative Bacteria: Enterobacteriaceae,” American Journal of Medicine, Vol. 119, No. 6, 2006, pp. S20-28.

[22]   Z. Q. Wei, Y. G. Chen, Y. S. Yu, W. X. Lu and L. J. Li. “Nosocomial Spread of Multi-Resistant Klebsiella pneumoniae Containing a Plasmid Encoding Multiple β-Lactamases,” Journal of Medical Microbiology, Vol. 54 No. 9, 2005 pp. 885-888. http://dx.doi.org/10.1099/jmm.0.46151-0

 
 
Top